Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial - Quiz - MDSpire

Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial

  • By

  • Keith J Chappell

  • Francesca L Mordant

  • Alberto A Amarilla

  • Naphak Modhiran

  • Benjamin Liang

  • Zheyi Li

  • Julia A Lackenby

  • Noushin Jaberolansar

  • Jake O’Donnell

  • Vivian Kienzle

  • Varsha Kommajosyula

  • Nicolas Tardiota

  • Jillian K Bennet

  • Christina L Henderson

  • Rhiannon L Dalrymple

  • Justin Goh

  • Kym Hoger

  • Marianne Gillard

  • Martina L Jones

  • Karen Hughes

  • Ben Hughes

  • James Barnes

  • Patrick C Reading

  • Charani Ranasinghe

  • Kanta Subbarao

  • Trent P Munro

  • Paul R Young

  • Daniel Watterson

  • November 25, 2025

  • 0 min

Share

Original Source(s)

Related Content